Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw an uptick in trading volume on Friday . 3,938 shares traded hands during mid-day trading, a decline of 13% from the previous session’s volume of 4,552 shares.The stock last traded at $17.6950 and had previously closed at $17.11.

Analysts Set New Price Targets

Several research firms have issued reports on AAPG. BTIG Research reiterated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research note on Wednesday. They set a “buy” rating and a $45.00 price objective for the company. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Up 4.2%

The firm’s 50 day simple moving average is $22.27 and its 200-day simple moving average is $24.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million for the quarter. On average, research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International in the second quarter valued at $391,000. UBS Group AG boosted its stake in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Finally, XY Capital Ltd boosted its stake in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.